A Long-Term Study of Navenibart in Participants With Hereditary Angioedema
Part of paid clinical trials in Scottsdale, Arizona.
- Sponsor
- Astria Therapeutics, Inc.
- Study ID
- NCT07204938
- Phase
- PHASE3
- Status
- Enrolling By Invitation
Conditions
- Hereditary Angioedema (HAE)
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- navenibart — DRUGNavenibart will be administered as a subcutaneous injection.
Study Details
This is a Phase 3 multicenter trial in 2 parts to evaluate the long-term safety and efficacy of navenibart in adult and adolescent participants with hereditary angioedema (HAE) who participated in STAR-0215-301 (NCT06842823; ALPHA-ORBIT). Part 1 provides all participants with navenibart in a dose-controlled fashion; Part 2 introduces a personalized dosing option (PDO) for participants based on individual needs.
Key Dates
- Start date
- Oct 1, 2025
- Status verified
- Jun 2026
- Primary completion
- Jun 30, 2031
- Completion
- Dec 31, 2031
Study Design
- Enrollment
- 145 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- PREVENTION
Arms
- Experimental: Adult Dosing Regimen 1Participants will receive 600 mg of navenibart every 3 months.
- Experimental: Adult Dosing Regimen 2Participants will receive 300 mg of navenibart every 3 months.
- Experimental: Adult Dosing Regimen 3Participants will receive 600 mg of navenibart every 6 months.
- Experimental: Adolescent Dosing Regimen 1Participants will receive 300 mg of navenibart every 3 months.
Primary Outcome Measure
Incidence of treatment-emergent adverse events (TEAEs) [ Time Frame: Day 1 through Month 48 ]
Locations (10)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Site 2 | Scottsdale | Arizona | 85251 | - |
| Site 3 | Little Rock | Arkansas | 72205 | - |
| Site 7 | San Diego | California | 92122 | - |
| Site 4 | Santa Monica | California | 90404 | - |
| Site 1 | Walnut Creek | California | 94598 | - |
| Site 5 | Centennial | Colorado | 80112 | - |
| Site 19 | Colorado Springs | Colorado | 80907 | - |
| Site 21 | Wheaton | Maryland | 20902 | - |
| Site 6 | Cincinnati | Ohio | 45236 | - |
| Site 9 | Hershey | Pennsylvania | 17033 | - |
Find similar trials in Scottsdale, AZ
Related Studies
- Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary AngioedemaPHASE2/PHASE3 · Enrolling By Invitation · Pharvaris Netherlands B.V. · Birmingham, Alabama
- Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAEPHASE3 · Recruiting · Pharvaris Netherlands B.V. · Birmingham, Alabama
- A Study of Navenibart in Participants With Hereditary AngioedemaPHASE3 · Enrolling By Invitation · Astria Therapeutics, Inc. · Birmingham, Alabama
- Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema PatientsPHASE1/PHASE2 · Recruiting · Institute for Asthma and Allergy · Wheaton, Maryland